The 2017 American Society of Clinical Oncology annual meeting is taking place in Chicago from last Friday through Tuesday. There have already been several companies that have updated shareholders with important data at the meeting. Here’s a look at some of the companies that Wall Street is watching.

• Agios Pharmaceuticals Inc AGIO 1.65% shares are down 3.0 percent after the company reported data from a Phase I study of AG-120 , for the cholangiocarcinoma dose escalation and expansion cohorts and data from a Phase I study of advanced solid tumors in the ClarIDHy Phase III multicenter, randomized double-blind study of AG-120 in patients with advanced cholangiocarcinoma with an IDH mutation. “The data in these presentations support Agios filing AG-120 by year-end and launching in 2018,” Oppenheimer analyst Leah Cann wrote.
• Verastem Inc VSTM 4.93% shares are down 4.1 percent after the company updated shareholders on its study entitled “Effect of FAK Inhibitor Defactinib on Tumor Immune Changes and Tumor Reductions in a Phase II Window of Opportunity of Malignant Plural Mesothelioma (MPM).” Cann wrote that Oppenheimer is currently not including defactinib in its models for Verastem but that the firm “believe[s] this is a promising compound and believe the data presented at ASCO are not only encouraging, but warrant the study of defactinib in more advanced clinical trials in lung cancers.”
• Exelixis, Inc. EXEL 2.48% shares are up 0.2 percent after the company presented Phase II data on Cabometyx in patients with recurrent/metastatic endometrial cancer (EC), data on a study of the role of ERBB signaling in RET-rearranged lung cancer and contribution of EGFR amplification to cabozantinib resistance, and Phase I data on cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors. “Data presented for Exelixis at 2017 ASCO are in indications we have not included in our outlook through 2021, but could provide growth after 2021,” Cann wrote.
• Epizyme Inc EPZM 0.68% shares are down 3.2 percent after the company released results from a solid tumor study of Tazemetostat. “The data presented on Sunday, June 4, 2017 supports our expectation that Epizyme could launch Tazemetostat in 2018,” Cann wrote.
• Amgen, Inc. AMGN 0.17% shares are up 0.1 percent after the company released new data from a Phase III study of Xgeva in treatment of multiple myeloma. “We anticipate Xgeva sales will increase to $2.1 billion in 2021 from $1.53 billion in 2016 and will account for 7.8 percent of sales and be the fifth-largest driver of sales growth,” Cann wrote.
• TESARO Inc TSRO 1.79% shares are down 4.9 percent after the company reported data on its Phase 1/2 TOPACIO combination study of niraparib and Keytruda and its Phase 1 TSR-042 study. “While we continue to believe niraparib has broad applicability and the IO pipeline has potential, with near-term volatility expected around competitive data (ARIEL-3 by end of June), we maintain our Neutral rating,” Baird analyst Michael Ulzwrote.
• Celgene Corporation CELG 0.46% shares are down…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!